Summary:
- The article discusses the need for a better business model to incentivize the development of new antibiotics to combat the growing threat of antibiotic-resistant "superbugs".
- It highlights the challenges faced by pharmaceutical companies in developing new antibiotics, including the high cost and low profitability of these drugs compared to other treatments.
- The article suggests that a combination of government funding, market-based incentives, and collaborative efforts between industry, academia, and policymakers are necessary to address this critical public health issue.